UK Trial to Test Roche's Alzheimer's Drug on Healthy Adults With No Memory Problems

Doctors in the UK are about to hand an experimental Alzheimer's drug to people who have no memory problems at all.

Starting Monday, September 7, the Surrey and Borders Partnership NHS Foundation Trust will begin screening the first European participants in a global trial called PrevenTRON. It's a phase III study aiming to recruit roughly 1,600 healthy adults aged 55 to 80 worldwide, according to The Guardian and The Telegraph. More than 15 UK hospitals and clinics, including sites in Scotland and Wales, are expected to join by the end of the year.

The Science Behind the Screening

Nobody gets the drug just for showing up. Participants first take memory tests to confirm they have no cognitive problems. Then they get a blood test measuring p-tau217, a protein biomarker that can flag Alzheimer's risk years before symptoms show up, according to the Daily Mail and The Telegraph.

The stakes of that blood test are real. Research cited by The Guardian found people with the highest p-tau217 levels had a 78% estimated chance of developing cognitive impairment within 10 years. The same biomarker test can identify Alzheimer's with up to 95% accuracy, per that research.

Only people whose p-tau217 levels fall in a specific elevated range move on to further screening, including MRI and PET scans, before they're randomly assigned to receive either the drug, trontinemab, or a placebo.

What Trontinemab Has Done So Far

Trontinemab, developed by the Swiss pharmaceutical company Roche, targets amyloid plaques, the toxic protein buildup in the brain linked to Alzheimer's. Early research found it cleared amyloid plaques in nine out of 10 people with early-stage Alzheimer's or mild cognitive impairment within 28 weeks, according to The Guardian. The Telegraph and Daily Mail both reported the same early data showed plaque clearance after just three monthly infusions.

Clearing plaques is not the same as preventing dementia. That's exactly what PrevenTRON is designed to test. Can hitting the biology early, before any symptoms, actually stop the disease from developing at all?

Professor Ramin Nilforooshan, a consultant psychiatrist and the trial's chief investigator, told The Telegraph the study marks "a fundamental shift from waiting for memory problems to emerge to trying to prevent them in the first place." He said Alzheimer's pathology is thought to begin five to 10 years before people typically seek treatment for memory problems, which is the entire rationale for intervening this early.

The Researcher's Own Warning

Nilforooshan isn't overselling it. He told The Telegraph plainly: "I'm not saying this trial is magic. It's an investigational medicine. We need to wait and see: will it work or not?"

Scientists have floated comparing this approach to "statins for the brain," per The Telegraph and Daily Mail, meaning healthy people at risk could eventually take preventive medication in mid-life the way millions take cholesterol drugs now. But statins have decades of outcome data behind them. Trontinemab has none yet for prevention. The trial itself is expected to run four to six years before anyone knows if it works.

The Fair Concern: Giving Drugs to People Who Aren't Sick

Anti-amyloid Alzheimer's drugs as a class have a track record of side effects, including brain swelling and bleeding, in patients who are already symptomatic. Asking healthy people with zero memory problems to take on years of an experimental drug's risk profile, for a benefit that is entirely theoretical until the data comes in, is a significant commitment.

The trial design answers part of that concern with a randomized, placebo-controlled structure and years of monitoring, which is the standard method for finding out whether risk is worth it. But that doesn't resolve the concern up front. It means volunteers are accepting real uncertainty in exchange for a shot at preventing a disease that Daily Mail, partnering with the Alzheimer's Society on its Defeating Dementia campaign, notes kills 76,000 people a year in Britain, making it the country's biggest killer.

Similar prevention-focused trials are already underway elsewhere in the amyloid disease space. UCSD's clinical trials listing shows an ongoing study testing another drug, acoramidis, in genetically at-risk but symptom-free adults for a related amyloid condition, transthyretin amyloidosis, suggesting PrevenTRON isn't an isolated experiment but part of a broader move toward hitting these diseases before symptoms start.

Trontinemab's ability to actually prevent Alzheimer's, as opposed to clearing plaques in a lab measurement, remains unproven. The answer won't come until the trial reports results, years from now.